specific clinical conditions: for example, status epilepticus, organ failure, and pregnancy.
Selective rather than routine monitoring of TDM was supported in a recent Cochrane Database review. 5 TDM is useful in specific clinical setting in which compliance, toxicity or overdose feature. The determination of serum drug concentrations can play a valuable role in guiding patient management provided that the measurements are undertaken with a clear indication; are interpreted appropriately and taking into consideration all the clinical details pertaining to the patient. 6 In a study in secondary care, only 20% of requests for TDM were thought to be appropriate. 7 The standard of care of patients with epilepsy in Chester was recorded as being poor prior to the introduction of the New Contract in 2004, 8 with only 19% of patients having a regular yearly review, 49% had not been reviewed in the previous year and 53% of adults who should be receiving shared care are not doing so.
Epilepsy was included as a quality indicator for the first time in the New GP Contract. 9 In the four quality and outcome framework indicators for epilepsy, TDM was not included. An educational intervention took place in 13 individual Chester practices from December 2001 to March 2003, which showed a significant improvement in documentation and review rates of patients with epilepsy in those practices influenced by the intervention. There was an even more marked improvement in review rates for those practices influenced by the education and the introduction of the New Contract. 10 The average yearly review rate for patients with epilepsy in Chester is now 95%. 
Methods
Although not part of the original research project, it was perceived a fall in the number of TDM might be a measure of the impact of the educational process. Early liaison with the Countess of Chester Hospital biochemistry laboratory showed there had indeed been a fall in requests from Chester and the Rural practices. Therefore a retrospective study to include the introduction of the New Contract was undertaken.
Chester practices
An educational intervention was completed in all practices after an individual patient audit and an epilepsy review template completed, the first session was in December 2001 and the last March 2003.
This was a 2 h tutorial (85% attendance of local GPs) in which Dr. Smith gave an overview of the diagnosis and management of epilepsy.
In a section of this talk Dr. Smith indicated that routine TDM was not required. Especially with valproate, as 'plasma-valproate concentrations are not a useful index of efficacy, therefore routine monitoring is unhelpful'. 12 He indicated TDM is useful in the following circumstances:
To check for compliance. If a patient was apparently toxic, and was on two different drugs either of which could be causing the toxicity. For phenytoin especially with poly-pharmacy and due to its unusual pharmacokinetics.
Rural practices
One large educational session took place in March 2004 for all the practices, in which Dr. Smith repeated the above lecture.
Ellesmere Port practices
One large educational session took place in March 2007 for all the practices. Dr. Minshall, now a GPwSI, gave the lecture
Wirral, Crewe, Warrington and Wrexham practices
No educational events were organised in these areas that has specifically included guidance on TDM.
The biochemistry departments at the Countess of Chester Hospital (Chester, Rural and Ellesmere Port), Arrowe Park Hospital (Wirral), Leighton Hospital (Crewe), Warrington General Hospital and Wrexham Maelor Hospital were contacted to provide the number of requests for TDM over the proceeding years (phenytoin, phenobarbitone, valproate and carbamazepine. Only two labs provided lamotrigine levels so these were excluded). These requests were from Primary Care only, not A&E, hospital inpatient or outpatient requests, and from April to April, as far back as records existed.
Statistics were analysed using Microsoft Excel computer software, using x 2 analysis.
Results
The following results were obtained from the five laboratories for the seven different areas (Table 1) .
These are represented graphically as percentage change from the baseline level for each area, in Fig. 1 for Chester, Rural and Ellesmere Port, and in Fig The statistical differences are illustrated in Table 2 between the different areas, each year is compared with the previous year. Significant changes are in bold.
There was no statistical difference between Chester and the Rural for any year. Compared with these latter two areas, in
The number of valproate assays is illustrated in Table 3 , the figure in brackets represents the percentage fall or increase from baseline.
Valproate
Discussion
The New Contract had a significant effect on the review rate of patients with epilepsy. If Primary Care clinicians thought routine TDM was normal practice, it would be expected the number of requests to rise. Equally in a population of patients previously poorly cared for, clinical indications may have arisen requiring an assay to be requested, hence a further possible increase in TDM. In the two areas, Chester and the Rural, influenced by education at the time of the introduction of the New Contract a fall in TDM was observed. In all the other areas, including Ellesmere Port, an increase in TDM was documented, but in the latter area there was a significant fall after their educational session. The effect of the educational input causing a significant fall on two separate occasions implies that a significant proportion of TDM, but maybe not all, were being performed routinely, and not for the indications in the guidelines. The valproate assay was singled out in the educational sessions as being particularly unhelpful. There was a reduction by some 56% in requests for this TDM in the areas who received the education compared with the other four areas where there was an overall reduction of 7% compared with the earliest baseline figure. These figures support the assumption the educational process had a major effect on TDM. In 2007/2008 there were still 611 requests from the seven areas, at a cost of approximately £6 per assay.
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It is possible that the overall fall is related to patients being taken off older drugs and being prescribed more recently introduced drugs, which do not have TDM recommended as part of their profile, and local laboratories do not perform assays. If a dosage change, two weeks between samples is recommended Fig. 3 . A proposed pathway for AED assay requests on line. * If two drugs chosen the system would deal with each request separately.
Equally the fall in requests may reflect patients having better control of their seizures with improvements in their care since QOF was introduced. Some variance may have occurred by studying different areas which may have different social groupings and hence prevalence of epilepsy. However, all the areas except Crewe have visiting consultants from the Walton Centre for Neurology.
NICE guidelines are excellent and have helped Primary Care to formalise patient care and referral onto secondary care. The number of guidelines in all areas has been overwhelming. A coordinated educational program needs to be provided by PCTs to deliver to GPs, the main, important points from the guidelines as they are released. This study shows that after an educational program in Chester, Rural and Ellesmere Port, the number of TDM fell significantly. TDM has fallen in the other areas, albeit slowly, which perhaps indicates there is a slow uptake of this recommendation in the management of patients with epilepsy.
Requests for blood tests in West Cheshire PCT are done on the computer and on line. Certain 'pop up' warnings and clinical guidance can appear informing GPs about individual tests. Information and guidance should be available to inform GPs in this way, as to when and when not to order TDM, especially valproate. A short pathway is proposed in Fig. 3 .
Further study needs to be undertaken to quantify the indications for TDM requests and do they meet the criteria advocated in guidelines, or are they in fact being done as a routine. This would need the co-operation of GPs documenting more data on the request form.
Conclusion
TDM is not usually required in the routine care of patients with epilepsy. TDM does not appear in either the New GP Contract QOF targets or in NICE guidelines in 2004 .
There has been a general trend for the number of TDM to fall since 2004. This fall has been statistically most significant in areas that have received additional education. PCTs should consider their educational provision when each NICE guideline is published, to highlight important and practical issues.
The continuing unnecessary request for assays has implications financially and on patient care.
